MagForce Company Profile
Business Description
MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company's proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries
| First Quotation | September 20, 2007 |
| Accounting standard | German statutory accounting (HBG) |
| Fiscal year end | December 31 |
| Executive Board | Dr. Andreas Jordan |
| Supervisory Board | Norbert Neef (Chairman) Dr. Stefan Elsser, Bernd Förtsch |
Share trading information | |
| ISIN | DE000A0HGQF5 |
| German Securities Identification Number (WKN) | A0HGQF |
| Ticker Symbol | MF6 |
| Market Segment | Entry Standard |
| Stock Class | no-par value shares |
| Equity Capital | 4.952.449,00 Euro |
| Outstanding Share | 4.952.449 shares |
| Shareholding Structure | Nanostart Group: 51.00 % |
| Deutsche Börse Listing Partner and Specialist, Applicant | Steubing AG |
| Designated Sponsor | Silvia Quandt & Cie. AG |
| Location | Max-Dohrn-Str 8, Building B5.2, 10589 Berlin |
